Agonist
Back to library
GLP-1Subcutaneous

Cagrilintide

Also known as: Cagri · AM833

Long-acting amylin analog. Activates calcitonin and amylin receptors to slow gastric emptying and suppress glucagon. Typically paired with semaglutide (CagriSema) for additive satiety.

At a glance

Half-life
6.6 days
Common route
Subcutaneous
Typical dose range
300–4,500mcg
Stability (reconstituted)
30days refrigerated

Best timing

Once weekly. When stacked with semaglutide, most users co-administer same day to consolidate side-effect window.

Contraindications

  • Active pancreatitis
  • Severe gastroparesis
  • Pregnancy
  • Type 1 diabetes (theoretical hypoglycemia stacking risk)

Watch symptoms

  • Nausea (often pronounced even without GLP-1 stacking)
  • Decreased appetite to the point of inadequate protein intake
  • Constipation
  • Injection site nodules
  • Mood flattening

Citations

The primary literature.

  1. 01Cagrilintide, a long-acting amylin analogue, for obesity (Phase 2)PubMed
  2. 02Semaglutide 2.4 mg plus cagrilintide 2.4 mg (CagriSema) in adults with overweight or obesityPubMed
Back to library